Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer

Article metrics

  • A Corrigendum to this article was published on 11 October 2011


Inhibition of the kinase suppressor of ras-1 (KSR1) gene by continuous infusion of phosphorothioate antisense oligonucleotides (ODNs) prevented growth of K-Ras-dependent human PANC-1 pancreatic and A549 non-small-cell lung carcinoma xenografts in nude mice, effected regression of established PANC-1 tumors and inhibited A549 lung metastases, all without apparent toxicity. These studies suggest KSR1 antisense ODNs as a treatment for Ras-dependent human malignancies, in particular pancreatic cancer, which lacks effective curative therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: KSR1 inactivation prevents A431 tumorigenesis.
Figure 2: KSR antisense ODNs abrogate PANC-1 and A549 tumorigenesis.


  1. 1

    Kornfeld, K., Hom, D.B. & Horvitz, H.R. Cell 83, 903–913 (1995).

  2. 2

    Sundaram, M., & Han, M. Cell 83, 889–901 (1995).

  3. 3

    Merlino, G.T. et al. Science 224, 417–419 (1984).

  4. 4

    Therrien, M. et al. Cell 83, 879–888 (1995).

  5. 5

    Almoguera, C. et al. Cell 53, 549–554 (1988).

  6. 6

    Smit, V.T. et al. Nucleic Acids Res. 16, 7773–7782 (1988).

  7. 7

    Bos, J.L. Cancer Res. 49, 4682–4689 (1989).

  8. 8

    Huron, D.R. et al. Clin. Cancer Res. 9, 1267–1273 (2003).

  9. 9

    Xing, R.H., Mazar, A., Henkin, J. & Rabbani, S.A. Clin. Cancer Res. 9, 1267–1273 (2003).

Download references


These studies were supported by National Institutes of Health grants CA42385 (R.K.) and CA52462 (Z.F.).

Author information

Correspondence to Richard Kolesnick.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Further reading